Join
Live feed
·
PRReleasevia Quantisnow
Aileron Therapeutics Inc. logo

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

ByQuantisnow·Wall Street's wire, on your screen.
ALRN· Aileron Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALRN (Aileron Therapeutics Inc.) and more on Quantisnow.